MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Lipocine Depreciation & Amortization 2011-2026 | LPCN
Annual Depreciation & Amortization Lipocine
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.7 K | 9.45 K | 380 | 3.55 K | 15.4 K | 18.6 K | 28.4 K | 32 K | 26.7 K | 14.6 K | 21.8 K | 42.6 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 42.6 K | 380 | 20.2 K |
Quarterly Depreciation & Amortization Lipocine
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 15.6 K | - | - | - | 8.51 K | - | - | - | 4.82 K | - | 6.88 K | 4.3 K | 1.72 K | - | - | - | - | - | 2.4 K | 1.6 K | 799 | - | 11.6 K | 7.72 K | 3.86 K | - | 14.2 K | 9.71 K | 5.26 K | - | 21.3 K | 14.2 K | 7.09 K | - | 23.7 K | 15.5 K | 6.65 K | - | 19.6 K | 8.72 K | 4.3 K | - | 9.39 K | 6.06 K | 3.03 K | - | 15.7 K | 10.5 K | 5.24 K | - | 31.6 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 31.6 K | 799 | 9.72 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Verastem
VSTM
|
30 K | $ 5.04 | -4.73 % | $ 349 M |  USA |
 |
VistaGen Therapeutics
VTGN
|
150 K | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M |  China |
 |
Aileron Therapeutics
ALRN
|
1 K | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
16 M | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
Xenon Pharmaceuticals
XENE
|
2.56 M | $ 54.48 | -1.89 % | $ 4.24 B |  Canada |
 |
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
ChemoCentryx
CCXI
|
3.14 M | - | - | $ 3.74 B | USA |
 |
Enochian Biosciences
ENOB
|
129 K | - | - | $ 40.5 M | USA |
 |
Summit Therapeutics
SMMT
|
146 K | $ 16.58 | -3.94 % | $ 12.4 B |  Britain |
 |
Alnylam Pharmaceuticals
ALNY
|
55.7 M | $ 317.36 | -3.29 % | $ 41.6 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
363 K | $ 4.29 | -3.6 % | $ 822 M | Canada |
 |
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
41 K | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | USA |
 |
Calithera Biosciences
CALA
|
300 K | - | -10.95 % | $ 876 K | USA |
 |
Fusion Pharmaceuticals
FUSN
|
1.34 M | - | - | $ 1.41 B | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | USA |
 |
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
31.6 M | $ 19.01 | -2.66 % | $ 889 M | USA |
 |
Gritstone Oncology
GRTS
|
7.59 M | - | 0.42 % | $ 213 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
920 K | $ 20.75 | -3.35 % | $ 3.44 B | USA |
 |
Aligos Therapeutics
ALGS
|
930 K | $ 6.66 | -5.4 % | $ 65.8 M | USA |
 |
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | USA |
 |
Alkermes plc
ALKS
|
27.2 M | $ 29.39 | -1.77 % | $ 4.84 B |  Irlanda |
 |
Cabaletta Bio
CABA
|
1.65 M | $ 2.68 | -4.96 % | $ 269 M | USA |
 |
AbbVie
ABBV
|
762 M | $ 209.4 | -0.81 % | $ 370 B | USA |
 |
AbCellera Biologics
ABCL
|
18.4 M | $ 3.27 | -2.39 % | $ 977 M | Canada |
 |
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | USA |
 |
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | Canada |
 |
Athira Pharma
ATHA
|
970 K | - | - | $ 269 M | USA |
 |
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | USA |